Mesothelioma News and Research RSS Feed - Mesothelioma News and Research

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.
Global experts meet at IASLC 17th World Conference on Lung Cancer in Vienna

Global experts meet at IASLC 17th World Conference on Lung Cancer in Vienna

Global lung cancer researchers and patient advocates today emphasized that new models of delivering care and communicating about cancer care play an important role in the fight against lung cancer. [More]
D.C. Council passes ‘Death with Dignity Act’ by a veto-proof 11-2 margin

D.C. Council passes ‘Death with Dignity Act’ by a veto-proof 11-2 margin

Compassion & Choices reports the District of Columbia is poised to become the seventh jurisdiction in the U.S. where medical aid in dying is authorized for terminally ill residents after the D.C. Council passed the D.C. Death with Dignity Act by a veto-proof 11-2 margin. [More]
Scientists identify genetic mutations in highly aggressive rhabdoid meningiomas

Scientists identify genetic mutations in highly aggressive rhabdoid meningiomas

Meningiomas are the most common primary brain tumors, but the term encompasses over a dozen subtypes that range from benign to highly aggressive. [More]
Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials. [More]
Scientists discover new option for treating malignant pleural mesothelioma

Scientists discover new option for treating malignant pleural mesothelioma

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. [More]
NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year. [More]
New NCCN Imaging AUC released for eight new cancers

New NCCN Imaging AUC released for eight new cancers

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types. [More]
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades. [More]
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
PD surgery improves quality of life in patients with malignant pleural mesothelioma

PD surgery improves quality of life in patients with malignant pleural mesothelioma

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
International scientists discuss new treatments for non small cell lung cancer

International scientists discuss new treatments for non small cell lung cancer

More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside. [More]
New drug shows promise against mesothelioma

New drug shows promise against mesothelioma

A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all. [More]
ONCOblot test shows promise in early detection of malignant mesothelioma

ONCOblot test shows promise in early detection of malignant mesothelioma

MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing. [More]

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet. [More]
Four unrelated families share identical BAP1 mutation that causes several cancers

Four unrelated families share identical BAP1 mutation that causes several cancers

University of Hawai'i Cancer Center researchers discovered members of four families, apparently unrelated and living in different states across the US, shared the identical mutation of a gene called BAP1 that causes mesothelioma, melanoma, renal carcinoma and other cancers. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Research finding offers hope for more powerful aspirin-like drugs

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed. [More]
Advertisement
Advertisement